Academic Journal

D-dimer for efficacy prediction in COVID-19 patients treated with paxlovid

التفاصيل البيبلوغرافية
العنوان: D-dimer for efficacy prediction in COVID-19 patients treated with paxlovid
المؤلفون: Daishi Li, Qingrong Wu, Wenrui Lin, Yanli Xie, Furong Zeng
المصدر: BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-7 (2024)
بيانات النشر: BMC, 2024.
سنة النشر: 2024
المجموعة: LCC:Infectious and parasitic diseases
مصطلحات موضوعية: COVID-19, Paxlovid, D-dimer, Efficacy prediction, Composite disease progression outcome, Infectious and parasitic diseases, RC109-216
الوصف: Abstract Background Paxlovid is one of the most effective antiviral therapies for COVID-19 patients, but no studies have explored the efficacy predictors of this drug. Methods To investigate whether D-dimer could be used as a predictor of paxlovid response. Our study included 394 patients diagnosed with COVID-19 who were treated with paxlovid at Xiangya Hospital from Dec 5, 2022, to Jan 31, 2023. We analyzed the composite outcome and all-cause mortality and compared the clinical and demographic data of patients with normal and abnormal D-dimer levels. Results We found that 324 patients (82.2%) with D-dimer levels were regularly compared with 70 patients (17.8%). Compared with patients with normal D-dimer levels, those with elevated D-dimer levels exhibited significantly reduced albumin levels, along with elevated levels of white blood cells, platelets, neutrophils, blood urea nitrogen, and procalcitonin. Kaplan–Meier survival curves showed that patients displaying increased D-dimer levels demonstrated a significantly higher incidence of composite disease progression within 28 days (p = 0.002) and all-cause death (p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-2334
Relation: https://doaj.org/toc/1471-2334
DOI: 10.1186/s12879-024-10254-x
URL الوصول: https://doaj.org/article/513b7def0f5247628818b81ec0d65ca5
رقم الانضمام: edsdoj.513b7def0f5247628818b81ec0d65ca5
قاعدة البيانات: Directory of Open Access Journals